



MATERIAL SAFETY DATA SHEET

Product Name: Clindamycin Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

**Manufacturer Name
And Address** Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

**Emergency Telephone
Hospira, Inc.** CHEMTREC: 800 424-9300
224 212-2055

Product Name Clindamycin Injection, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Clindamycin Phosphate
Chemical Formula $C_{18}H_{34}ClN_2O_8PS$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Clindamycin Phosphate	15	24729-96-2	GF2625000
Water	84	7732-18-5	ZC0110000
Benzyl Alcohol	0.9	100-51-6	DN3150000

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used for the treatment of serious infection. The active ingredient may cause skin rash or allergic reaction upon ingestion. It has also been reported to cause irritation of the gastrointestinal tract in some patients.

**Occupational Exposure
Potential** Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact with solution.

Signs and Symptoms No signs or symptoms from occupational exposure are known. In clinical use, clindamycins have been associated with rashes, colitis (diarrhea, abdominal cramps) and irritant responses.

**Medical Conditions
Aggravated by Exposure** Data suggest skin, eye or respiratory lesions, pre-existing gastrointestinal distress or hypersensitivity to clindamycin or related antibiotics (e.g. lincomycin).

Product Name: Clindamycin Injection, USP

4. FIRST AID MEASURES

Eye Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability:	Non-flammable.
Fire & Explosion Hazard:	None
Extinguishing Media:	Use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting Procedures	No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Absorb liquid with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.
-----------------------------------	--

7. HANDLING AND STORAGE

Handling	No special handling required.
Storage	No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).
Special Precautions	Protect from freezing and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Clindamycin Phosphate	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: 2 mg/m ³
Benzyl Alcohol	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Clindamycin Injection, USP

Respiratory Protection	Respiratory protection is not needed during normal product use.
Skin Protection	If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.
Eye Protection	Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.
Engineering Controls	Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Clear liquid
Odor	None
Boiling Point	Approximately that of water (100 °C, 212 °F).
Freezing Point	Approximately that of water (0°C, 32 °F).
Vapor Pressure	Approximately that of water (17.5 mm Hg at 20 °C).
Vapor Density (Air=1)	Not Applicable
Evaporation Rate	Not Applicable
Bulk Density	Not Applicable
Specific Gravity	Approximately that of water (1.0).
Solubility	Not Applicable
pH	2.7 - 4.0

10. STABILITY AND REACTIVITY

Chemical Stability	Stable under standard use and storage conditions.
Incompatibilities	None
Hazardous Decomposition Products	Oxides of nitrogen and HCL.
Hazardous Polymerization	None

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity - Oral

Ingredient(s)	Percent	Test Type	Value	Units	Species
Clindamycin	100	LD50	2193 - 2618	mg/kg	Rats Mice
Benzyl Alcohol	100	LD50	1040 - 3100	mg/kg	Animals

LD50 is the dosage producing 50% mortality.

Product contains approximately 15% Clindamycin.

Mutagenicity	Not Determined.
Target Organ Effects	In clinical use target organ effects include gastrointestinal tract.

Product Name: Clindamycin Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Available

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status Not Regulated
CERCLA Status Not Regulated
SARA Status Not Regulated
RCRA Status Not Regulated
PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator Global Occupational Toxicology
Date Prepared September 15, 2005
Date Revised October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.